Dublin, July 31, 2020 (GLOBE NEWSWIRE) -- The "Menopausal Hot Flashes - Global Market Outlook (2019-2027)" report has been added to ResearchAndMarkets.com's offering.
The Global Menopausal Hot Flashes market accounted for $10.26 billion in 2019 and is expected to reach $18.99 billion by 2027, growing at a CAGR of 8.0% during the forecast period.
Growing population of elderly women across the globe and technological advancement in the development of new drugs for the treatment are the major factors driving market growth. However, availability of generic medicines is restraining market growth.
Based on distribution channel, the retail pharmacies segment is likely to have a huge demand as it is preferred by large number of consumers such as pharmaceutical stores, hospitals, drugs stores and clinics. Factors such as the growing female population and growth in the number of retail outlets in developing and emerging countries such as China and India will fuel the demand for women's health products.
By geography, North America is going to have a lucrative growth during the forecast period due to growing baby boomer population, the high health care expenditure and large number of prescriptions of hormonal as well as non-hormonal treatment products.
Some of the key players profiled in the Menopausal Hot Flashes Market include Allergan plc, GlaxoSmithKline plc, Hisamitsu Pharmaceutical Co Inc, Merck & Co Inc, Mylan N.V, Novartis AG, Novo Nordisk A/S, Pfizer Inc, Teva Pharmaceutical Industries Ltd and TherapeuticsMD Inc.
What the report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2018, 2019, 2020, 2024 and 2027
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities and recommendations)
- Strategic analysis: Drivers and Constraints, Product/Technology Analysis, Porter's five forces analysis, SWOT analysis, etc.
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company Profiling with detailed strategies, financials and recent developments
- Supply chain trends mapping the latest technological advancements
Key Topics Covered
1 Executive Summary
2 Preface
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Application Analysis
3.7 Emerging Markets
3.8 Impact of COVID-19
4 Porters Five Force Analysis
5 Global Menopausal Hot Flashes Market, By Type
5.1 Introduction
5.2 Oral Liquid
5.3 Pill
6 Global Menopausal Hot Flashes Market, By Treatment Type
6.1 Introduction
6.2 Alternative Treatment
6.2.1 Vitamin E
6.2.2 Herbal Medicines
6.2.3 Black Cohosh
6.3 Hormonal Treatment
6.3.1 Estrogen
6.3.1.1 Vivelle, Vivelle-Dot
6.3.1.2 Premarin
6.3.2 Estrogen-Progesterone Combination
6.3.2.1 Duavee
6.3.2.2 Prempro
6.3.3 Progesterone
6.3.3.1 Prometrium
6.4 Non-Hormonal Treatment
6.4.1 Clonidine
6.4.2 Gabapentin
6.4.3 Pregabalin
6.4.4 Brisdelle
6.4.5 Antidepressants
6.4.5.1 Desvenlafaxine
6.4.5.2 Fluoxetine
6.4.5.3 Paroxetine
6.4.5.4 Venlafaxine
7 Global Menopausal Hot Flashes Market, By Pipeline Analysis
7.1 Introduction
7.2 Phase III Drugs
7.3 Phase I and II Drugs
8 Global Menopausal Hot Flashes Market, By Distribution Channel
8.1 Introduction
8.2 Hospital Pharmacies
8.3 Online Pharmacies
8.4 Retail Pharmacies
9 Global Menopausal Hot Flashes Market, By Application
9.1 Introduction
9.2 51-55 Year Old Woman
9.3 46-50 Year Old Woman
9.4 40-45 Year Old Woman
10 Global Menopausal Hot Flashes Market, By Geography
10.1 Introduction
10.2 North America
10.3 Europe
10.4 Asia-Pacific
10.5 South America
10.6 Middle East & Africa
11 Key Developments
11.1 Agreements, Partnerships, Collaborations and Joint Ventures
11.2 Acquisitions & Mergers
11.3 New Product Launch
11.4 Expansions
11.5 Other Key Strategies
12 Company Profiling
12.1 Allergan plc
12.2 GlaxoSmithKline plc
12.3 Hisamitsu Pharmaceutical Co. Inc.
12.4 Merck & Co Inc.
12.5 Mylan N.V.
12.6 Novartis AG
12.7 Novo Nordisk A/S
12.8 Pfizer Inc.
12.9 Teva Pharmaceutical Industries Ltd.
12.10 TherapeuticsMD Inc.
For more information about this report visit https://www.researchandmarkets.com/r/v50n5x
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.